Bayer's Dual Front: Boardroom Reshuffle Meets Legal Cliffhanger

Bayer faces pivotal U.S. Supreme Court hearing on glyphosate litigation and a supervisory board reshuffle, as analysts upgrade stock on hopes for legal clarity and strong pharma growth.

A significant overhaul of Bayer’s supervisory board is set to coincide with a pivotal U.S. Supreme Court hearing, framing a critical fortnight for the German conglomerate. As shareholders prepare for the annual meeting, analysts are shifting their stance on the stock, betting that long-standing legal uncertainties may finally be approaching resolution.

The company’s upcoming virtual Annual General Meeting on April 24, 2026, will see a notable changing of the guard. Long-serving supervisors Paul Achleitner and Colleen A. Goggins are stepping down. Their proposed successors are OMV CEO Alfred Stern, expected to bring leadership and governance expertise, and former Cargill executive Marcel Smits. On the financial front, shareholders are set to receive a meager dividend of just 0.11 euros per share for the 2025 financial year, with the ex-dividend date slated for April 27.

Concurrently, the company faces a monumental legal milestone. Hearings in the case "Durnell v. Monsanto" are scheduled before the U.S. Supreme Court on April 27, with a ruling expected by the end of June 2026. The core issue is whether federal law preempts state-level liability claims. CEO Bill Anderson has framed the Court's decision to hear the case as a major step toward regulatory clarity. A favorable ruling could drastically limit the remaining wave of glyphosate litigation that has plagued Bayer since its Monsanto acquisition.

This potential for reduced legal risk is beginning to color analyst sentiment. DZ Bank analyst Peter Spengler upgraded his rating on Bayer from "Sell" to "Hold," raising his price target from 42 to 44 euros. He cited increasingly calculable glyphosate litigation risks due to the pursued settlement, alongside lower pension provision estimates and a higher valuation multiple for the agriculture business. UBS reaffirmed its "Buy" rating with a more bullish price target of 52 euros.

The financial burden, however, remains immense. The company anticipates spending approximately five billion euros on glyphosate litigation payments in 2026 alone. This outflow is a key driver behind the projected rise in net financial debt, which is expected to swell to 33 billion euros by year-end. For 2026, Bayer forecasts group sales of up to 47 billion euros and an adjusted EBITDA of around ten billion.

Operational momentum provides a crucial counterweight. The pharmaceutical division is a standout, driven by the kidney and heart drug Kerendia. Following an expanded EU approval for treating heart failure, the drug posted currency-adjusted growth exceeding 88% recently. Management is now targeting peak sales of over three billion euros for Kerendia, with a new U.S. leadership structure from May aimed at accelerating this growth.

The stock’s performance reflects this turbulent yet hopeful landscape. Shares recently closed at 40.79 euros, trading just below the 50-day moving average. On a year-to-date basis, the equity has delivered a striking gain of over 95%.

The condensed calendar of events will soon provide clearer signals. Following the AGM and Supreme Court hearing, the company will publish its first-quarter results on May 12. These figures will be scrutinized for evidence that the pharmaceutical division’s robust growth can sustainably offset the formidable legal and financial pressures facing the group.